treatment of infant AML
AML genome
infant AML Infant acute myeloid leukemia
fetal stage-specific non-coding RNAs
vulnerable fetal stage-specific background of infant AML
non-coding transcriptome
knowledge of non-coding RNAs
transcriptional landscape
comprehensive transcriptomic atlas of infant AML
unrecognized Achilles heel of infant AML
fetal stem cells
standards of AML diagnosis
fetal cell of origin
non-protein-coding genome
cell-specific expression of long non-coding RNAs
cancer treatment
fetal hematopoietic stem cells
fertile transcriptional background
diversity of transcriptional products
adult cells
developmental stage
innovative treatment approaches
oncogenic interactome
oncogenic programs
leukemia progression
permissive basis
sustaining cancer
high prevalence of unfavorable features
chromatin
increased susceptibility
therapy-related toxicities
current obstacles
therapeutic interventions
need
enormous number
presumed wastelands
dismal prognosis
various research areas
paradigm shift
recent breakthroughs
biobank of patient
derived xenografts
preclinical RNA
discovery
particular oncogenes
transformation
expertise